IGFBP2 and cancer: In relation to serum IGFBP‐2, the findings in this study confirm observations in other reports that baseline IGFBP‐2 in patients with cancer is prognostic for poorer outcome in patients with cervical 36, pancreatic 37, and ovarian 11 cancer.